Posterior capsule opacification (PCO) is a common complication of cataract surgery. Using adenovirus(Ad)-mediated gene transfer, we overexpressed the proapoptotic molecules p53, procaspase 3, Bax, and TRAIL to induce therapeutic programmed cell death of residual lens cells to prevent PCO. Overexpressed TRAIL did not induce apoptosis in cultured rabbit lens cells or in human lens cells. Overexpressed p53 induced apoptosis of lens cells in vitro and ex vivo, but was unable to prevent PCO in vivo. Overexpressed procaspase 3 was associated with engagement of many components of the apoptotic pathway, including cleavage of intracellular caspase targets such as PARP and inter-nucleosome DNA fragmentation. Even when only slightly overexpressed, Bax caused apoptosis of transduced rabbit and human lens cells by engaging the mitochondrial pathway, including catalytic activation of the caspases. A single in vivo injection of Ad vectors expressing either Bax or procaspase 3 into the capsular bag at the end of phacoemulsification prevented PCO in rabbits. These experiments show that Ad-mediated Bax or procaspase 3 overexpression is capable of inducing therapeutic programmed cell death in vitro and in vivo in residual lens cells and preventing PCO in a rabbit model of PCO. Manipulation of proapoptotic molecule expression could be a novel gene therapy approach for prevention of PCO.
Introduction
Cataract is a common pathology with a high incidence that is related to life expectancy. During the last two decades, cataract surgery has undergone huge improvements in terms of visual rehabilitation since the development of phacoemulsification. Postoperative prognosis has been greatly enhanced by the almost complete elimination of postoperative complications. The only complication that has not been solved up to now is posterior capsule opacification (PCO). 1 PCO incidence, which was approximately 50% in adults and 100% in children, has been lowered but not eradicated by improvements of intraocular lens design such as the 'square edge' concept. 2 Thus, in 2005, the problem of PCO remains unsolved. The development of an alternative therapy for preventing PCO is of critical importance since laser YAG treatment of PCO can lead to severe complications such as retinal detachment and macular edema. Furthermore, the importance of preventing PCO has been increased by the recent potential development of accommodative intraocular lenses, multifocal intraocular lenses, and lens-refilling replacement. 3 These procedures could allow both far and near vision but can only be proposed if the capsule remains clear. Thus, eradicating PCO will improve the visual comfort of cataract surgery patients and will open the road to an innovative surgical treatment for presbyopic patients over 40 years of age.
PCO, which is an opacification of the capsular bag, results from the presence of lens epithelial cells remaining after surgery. 4 It occurs in three successive steps: proliferation, migration, and metaplasia of lens epithelial cells. To prevent PCO, we propose to introduce a cytotoxic gene into residual lens epithelial cells to kill the cells while preserving the surrounding ocular tissues. For this purpose, in situ gene transfer represents an attractive alternative because viral particles can be delivered directly into the capsular bag. The most extensively studied approach to date to eliminate dividing cells is the 'suicide' gene strategy, which involves targeted delivery of genes encoding metabolic enzymes that convert innocuous prodrugs into toxic metabolites. [5] [6] [7] The prototype for this approach is herpes simplex virus 1 thymidine kinase (HSV-tk), which converts the dideoxynucleoside prodrug ganciclovir (GCV) into its phosphorylated form, leading to DNA chain termination and cell death. We previously demonstrated the efficacy of this suicide gene to prevent PCO in a rabbit model 8, 9 but there are three major weaknesses for its clinical use: (i) the need for repeated intraocular injections of GCV, which reduces the possibility of treating patients, (ii) a significant although partial efficacy (probably due to the fact that not all of the residual epithelial cells divide immediately after phacoemulsification), and (iii) toxic side effects due to a high concentration of GCV. We thus suggested that this strategy could be improved by using an apoptosis inducer gene to remove the residual lens epithelial cells. Apoptosis, or programmed cell death, is a physiological process essential for normal development and maintenance of homeostasis in many organisms. 10 This cellular suicide can be triggered by the constitutive expression of different genes known to act through different caspase-dependent or -independent pathways to induce apoptosis. The main reason for using an apoptosis inducer gene to improve the efficiency is that all residual lens epithelial cells must be removed to avoid PCO. We have identified in vitro at least three pathways of the apoptotic process whose activation could induce apoptosis of lens cells: activation of the caspase cascade through the overexpression of death receptors;
11 release of apoptotic molecules such as cytochrome c into the cytosol (mitochondrial pathway); 12, 13 and the p53 pathway 14, 15 ( Figure 1b) . On the basis of these observations, we suggested that induction of one of these three steps by gene therapy may result in therapeutic apoptosis of residual lens cells and prevention of PCO. 16 Here, we tested two of the highly sensitive artificial death switches based on death receptor-signaling intermediates TRAIL and caspase 3, and two proapoptotic proteins such as p53 and Bax currently used in anticancer therapy (Figure 1 ). Through the binding of its death domain-containing receptors, TRAIL can induce apoptosis by a Fas-associated death domain (FADD)-dependent mechanism.
11, 17, 18 The caspase-3 gene encodes a protease normally activated at the end of the cascade. Caspase-3 is activated either after activation of the apoptotic machinery through interaction with FADD, which in turn activates caspase-8 thereby initiating the cascade leading to cell death, or through activation of the mitochondrial pathway. 10 Bax, 19 which is activated by p53, associates with Bcl-XL to open mitochondrial membrane pores, leading to the release of cytochrome c into the cytoplasm. Cytochrome c then activates the caspase cascade via Apaf-1 and caspase-3. 12, 13, 20 In normal cells, p53 controls cell proliferation, senescence, and/or mediates apoptosis in response to stress, cell damage, or ectopic oncogene expression, properties which make p53 the prototypic tumor suppressor gene. [21] [22] [23] In the lens, p53 overexpression could counteract the proliferation of nontumor cells. Using transgenic mice, Morgenbesser et al. showed that lens-specific overexpression of p53 induces death of the lens cells, which in turn induces microphthalmia resulting from a defect in ocular fiber formation. 
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In the present study, replication-defective Ad vectors expressing proapoptotic proteins were constructed. Ad vectors were chosen because they can transduce 100% of lens cells in vitro and in vivo, 9 and there is essentially no insertion of the vector into the host genome (epigenomic). Ad vectors encoding the proapoptotic genes were used in vitro (rabbit lens cells), ex vivo (human lens cells from capsular bag), or in vivo (rabbit model of phacoemulsification). Our aim was to compare the efficiency of proapoptotic gene transfer in inducing apoptosis of lens cells and preventing PCO.
We demonstrate here that Ad-mediated overexpression of procaspase-3 and Bax induced therapeutic programmed lens cell death by triggering the caspase cascade or the mitochondrial pathway, and prevented PCO.
Results
Several serotype 5 Ad vectors encoding different proapoptotic genes were constructed to compare the efficiency of several proapoptotic genes in preventing PCO. 9 Four vectors were constructed (Figure 1b ) expressing proteins involved in three apoptotic pathways: activation of the caspase pathway through the activation of members of the TNF-R family (AdTRAIL, AdCaspase-3), release of apoptotic molecules such as cytochrome c into the cytosol (mitochondrial pathway) (AdBax and AdCaspase 3), and the p53 pathway (Adp53). We hypothesized that manipulation of any of these three steps of the apoptotic pathway by gene therapy may result in induction of therapeutic apoptosis of residual lens cells and prevention of PCO in vivo. The proapoptotic genes were under the transcriptional control of the strong CMV promoter (Figure 1a ). (Figure 2a and c). Endogenous procaspase 3 was undetectable in lens cells, but a significant increase in level was found post-transduction with Adcaspase 3. Adenovirus-mediated procaspase 3 overexpression was followed by autocatalytic activation of the overexpressed protein with the presence of a 17 kDa protein (Figure 2b ). Lens cells naturally express detectable levels of TRAIL (Figure 2d ). The transduction did not induce a significant overexpression of the ectotopic molecule TRAIL in lens cells, while the same vector used in cells that do not express TRAIL induced ectopic expression of the protein.
Adenoviral

Inhibition of cell proliferation and induction of apoptosis of rabbit lens cells in vitro
We next analyzed the efficacy of the transduction to abolish rabbit lens cell proliferation in vitro and to induce apoptotic death of rabbit lens cells.
Despite TRAIL expression (Figure 2d ), we were unable to detect internucleosomal degradation by TUNEL (not shown) or cleavage of apoptotic substrates such as poly (ADP-ribose) polymerase (PARP) in rabbit lens cells, suggesting that ectopic expression did not induce therapeutic apoptosis of lens cells in vitro or ex vivo. We then focused on more proximal molecules such as p53, procaspase 3, and Bax. Their effects were evaluated using three types of experiments: (i) cell proliferation assayed by daily evaluation of viable cells, (ii) percentage of apoptotic cells by Annexin V analysis, and (iii) p21 expression (whose transcription is induced by p53) and PARP activation by Western blotting analysis. This increase in PARP and p21 levels was not observed after transduction of AdeGFP. Adp53, AdCaspase 3, and AdBax were equally effective in inducing apoptosis 72 h post-transduction in RLE cells.
Induction of apoptosis of human lens cells obtained from anterior capsules after surgical rhexis
We next analyzed the efficacy of the transduction to induce the apoptotic death of lens cells ex vivo using human lens cells cultured from rhexis obtained after phacoemulsification. Apoptosis was evaluated using Annexin-V analysis ( Figure 3e ). Adp53, AdCaspase-3, and AdBax were all equally effective in inducing apoptosis 72 h post-transduction. We did not detect residual living cells in the rhexis transduced by AdCaspase-3 or AdBax or by Adp53, 48 or 96 h posttransduction, respectively. 
In vivo experiments
Following phacoemulsification of New Zealand albino rabbits, they spontaneously develop PCO and lens regrowth. We performed phacoemulsification and at the end of the surgical procedure, vectors encoding the different proapoptotic proteins were injected in the capsular bag to assess PCO prevention. We evaluated secondary cataract formation for 2 months post surgery by quantifying the surface of the regenerated opacified area. 25 We used a scoring system ranging from 0 to IV (Figure 4a) .
There was no difference between the control and the Adp53-treated groups with respect to the severity of PCO (P ¼ 0.33) (Figure 4b ). In contrast, the treatments using AdCaspase-3 and AdBax vectors were efficient (Po0.001). In the control groups, six out of nine rabbits developed a severe PCO, while no PCO was observed in the AdCaspase-3-or the AdBax-treated groups.
Furthermore, in all groups, all the eyes had mild to moderate anterior chamber inflammation that resolved by the end of the first postoperative week and the corneas remained clear. For all tested vectors (AdCaspase 3, AdBax, Adp53, and AdeGFP) and for nontransduced cells, no cell death was observed in the corneal endothelium (Figure 4c ).
Discussion
The absence of currently available treatments to prevent PCO combined with the necessity to eradicate PCO due to new potential surgical concepts has driven interest to develop new experimental therapies. Elegant proposals consisted of inducing a de novo synthesis of a crystalline lens from the residual lens epithelial cells or using growth factors, thus avoiding the differentiation of residual lens cells into fibroblast-like cells (which could cause wrinkles, folds, and opacities of the capsulethat could result in PCO and IOL decentralization). 26, 27 However, these strategies are currently difficult to perform. Here, we propose an alternative strategy using transient gene therapy. Considering that PCO develops from residual lens cells and that this cell proliferation process can be observed immediately post surgery, we reported previously that it was possible to lower the incidence of PCO by killing lens cells using GCV after transduction with an Ad vector encoding HSV-tk. 8, 9 This provided the first proof-of-concept study on the use of gene transfer as a potential treatment for PCO. However, as mentioned, there are clinical drawbacks.
Our strategy was to remove the residual lens cells by inducing apoptosis. The present investigation was performed to identify molecules of the apoptotic machinery that can be used as therapeutic targets to induce apoptosis of residual lens epithelial cells in vitro, ex vivo, and in vivo to prevent PCO. The PCO model we used is the rabbit model without implantation, which has the disadvantage of not reproducing precisely the clinical situation (of a phacoemulsification associated with an implantation), but has the advantage of avoiding additional bias that could influence the development of PCO (such as the respective diameters of the lens optic and the capsulorhexisy). Brand et al. showed that in vitro E1-DE1DE3 Ad vectors could induce apoptosis if applied at a high MOI. 25 To distinguish between vector-cytotoxicity and the effect of the transgene, we compared the We found that modest doses of vectors led to efficient transduction (495% GFP-positive cells when using 100 physical particles/cell) and we did not notice any cytotoxicity 7 days post-transduction (data not shown). These data demonstrated that under our conditions, cell apoptosis was due to transgene expression rather than to the vector. We first overexpressed TRAIL, a member of the TNF family of proteins and a type II membrane protein.
Overexpression of TRAIL was unable to induce apoptosis of lens cells. The molecular mechanisms for the inability of overexpressed TRAIL to induce activation of apoptosis of proliferating cells are unclear. Previous reports demonstrated that ectopic overexpression of TRAIL is followed by apoptosis of tumor or proliferating cells, 11, 17, 18 while no apoptosis could be noticed in normal nonproliferating cells. Under physiological conditions, these death-signaling events are inhibited by as yet unknown survival factors. Residual lens cells may not have a sufficient proliferation rate to be sensitive to the apoptotic action of TRAIL. Similar results were obtained using Ad vector encoding caspase 8 (data not shown).
One of the proapoptotic proteins we selected was p53. The p53 cDNA encodes a nuclear phospho-protein that controls the switch from the G1 to S phase, induces apoptosis of the cells, or controls DNA synthesis. 24 We found that p53 overexpression induced apoptosis of rabbit and human lens cells in vitro and ex vivo. In contrast, p53 overexpression could not prevent PCO, suggesting that it probably does not induce apoptosis of the lens cells in vivo. p53 is inhibited during normal cell growth by the MDM2 proto-oncogene through either ubiquitin-dependent p53 degradation in the cytoplasm or repression of p53's transcriptional activity in the nucleus. 21, 22 Bax overexpression causes cytochrome c release, activation of the caspase pathway, and apoptosis of rabbit and human lens cells in vitro and ex vivo. It is possible that cytoplasmic release of the mitochondrial protein Smac 12, 13 contributed to the apoptotic effect of overexpressed Bax. These observations imply that manipulation of Bax expression has broad applications for the induction of therapeutic apoptosis. 20 We also activated the caspase pathway by overexpressing procaspase-3. This approach was based on the observations that plasmid-induced ectopic overexpression of several caspases is followed by apoptotic death of the target cells. 10 Here, we showed that Bax and caspase-3 overexpression was effective both in the induction of the apoptotic death of the lens cells and in the prevention of PCO.
The use of genes such as Bax or procaspase-3 represents an evolution from HSV-tk as the former two proteins are cytotoxic without requiring exposure to substances like GCV. On the basis of the results presented in this report, we think that the main issue is that the use of apoptosis will cause lens cell death and has a significant effect on reducing PCO. The rabbit model is a very demanding model of PCO and results using non-human primates may be even better. A potential problem with this approach is that killing all residual lens epithelial cells may ultimately result in capsular defects as growth and/or maintenance of the capsule requires living lens cells. As in the human lens capsular lamination, which is thought to be a sign of active capsule production, disappears from the posterior capsule by the age of 6 years and from the anterior capsule in middle age 29 (for a review, see Krag and Andreassen 30 ), this is not expected to be a problem in elderly patients. However, proper maintenance of the capsule after cataract surgery in children may be a cause for concern. This question can now be addressed using the rabbit model.
If our study has the merit of demonstrating the efficacy of apoptotic induction for treating PCO, it becomes necessary that to have any therapeutic significance, transgene expression must be restricted to the remaining epithelial cells. We proposed a surgically obtained specificity by 'jailing' the vector inside the capsular bag using a viscoelastic substance acting as a plug, which obliterated the small hole of the capsulorhexis, avoiding the extravasation of the vector to the surrounding tissues. The validity of this strategy is confirmed by the absence of corneal endothelial cell death. A recently proposed surgical strategy for delivery inside the capsular bag using a device called 'PerfectCapsuleTM' could be yet another efficient way for selective delivery of the apoptotic vector. 31 For our part, we are currently working on improving this strategy by using optimized viscoelastic materials. However, we believe that this method of surgically obtained specificity must be reinforced by a second level of nonsurgical specificity to avoid cell death in adjacent tissues. We are currently collecting data to secure gene transfer only to lens cells by using lens cell-specific promoters.
In conclusion, although procaspase-3 or Bax overexpression is a powerful way to induce apoptosis in an experimental model of PCO, further work is needed before this approach can be used for the treatment of human disease.
Materials and methods
Reagents
Fetal calf serum (FCS) and culture media were purchased from BioWhittaker (France). Mouse monoclonal anti-p53 antibody (Bp53-12) was from Santa Cruz Biotechnology (TEBU, Le Perray en Yvelines, France). Mouse antihuman Bax, TRAIL, PARP, or p21 were purchased from BD Biosciences/Pharmingen (France). FITC-peroxidaseconjugated anti-rabbit and anti-mouse secondary antibodies, the anti-b-actin and FITC-labeled anti-mouse monoclonal antibodies, and a liquid alkaline phosphatase detection kit were from Sigma (St Quentin-Fallavier, France). Mouse-anti caspase-3 (CPP32) monoclonal antibody was from Chemicon International (France).
Cell culture
The 293 cells (a transformed human embryonic kidney cell line) were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and maintained as monolayers at 371C in a humidified 5% CO 2 atmosphere in DMEM medium supplemented with 10% FCS.
Rabbit lens epithelial cells (RLE), obtained from rabbit capsular bag, 8 were grown in Hank/F12 medium supplemented with 20% FCS. The different cDNA cloned into the adenoviral plasmid (pShuttle) were obtained by PCR amplification. The primers used to generate pAdp53 were 5 0 ATAAGAATG CGGCCGCCATGGAGGAGCCGCAGTCAG and 5 0 CCC AAGCTTTCAGTCTGAGTCAGGCCCTTCTGTCTTGAA CATGAG. We generated PCR fragment corresponding to human Bax cDNA by using the primers 5 0 CCCAAGCTT ATGGACGGGTCCGGGGAGCAGC and 5 0 CCCAAGCT TCAGCCCATCTTCTTCCAG. We generated PCR fragment corresponding to human caspase-3 by using the primers 5 0 CCCAAGCTTGGTATCCATGGAGAACACTG and 5 0 CCCAAGCTTCCAACCATTTCTTTAGTGATA. We generated a PCR fragment corresponding to human TRAIL cDNA by using the primers 5 0 CCCAAGCTTCAGGATC ATGGCTATGATGG and 5 0 CCCAAGCTTCCAGGTCAG TTAGCCAAC. Replication-defective (DE1,E3) Ad vectors expressing caspase-3, TRAIL, p53, or Bax under the transcriptional control of the CMV promoter were constructed with the AdEasy System (Qbiogen, France). Initially, a PCR-amplified HindIII fragment containing the different proapoptotic gene was subcloned into HindIII-digested pshuttleCMV to obtain shuttle vectors pAdp53wt, pAdBax, pAdCaspase 3, and pAdTRAIL ( Figure 1a ). To generate recombinant Ad plasmids, shuttle vectors containing the different cDNA were linearized with Pme1, mixed at a 10:1 ratio with pAdEasy and cotransfected (1 mg total) into Escherichia coli strain BJ5138. The smaller kanamycinresistant colonies, typically containing the large recombinant plasmids, were analyzed by restriction digests. Replication-defective vectors (Adp53wt, AdBax AdCaspase3, and AdTRAIL, as well as the control vector AdeGFP (encoding enhanced green fluorescent protein (GFP), a generous gift from the GVPN, Genethon, Evry)) were produced by transfection of 293 cells with a single isolate of each recombinant Ad vector. The recombinant adenoviruses were propagated in 293 cells, and purified by cesium chloride gradient. Viral titers were determined by optical absorbance at 260 nm (1OD ¼ 1 Â 10 12 physical particle/ml).
On day 1, 1 Â 10 5 cells were seeded in a six-well plate. The following day, one of the six wells was trypsinized and the cells were counted, to standardize the MOI. Transductions were performed in 5% CO 2 incubators at 371C for 1 h using 500 ml of transduction medium (the same medium used for each cell line+2% FCS) with agitation. Pilot experiments with AdeGFP were used to estimate the optimal MOI for RLE cells and rhexis.
Immunoblotting
Cells were seeded in 3.5 cm dishes to 50% confluence before transduction. Total protein extracts were prepared 48 h post-transduction, by lysing the cells in 150 ml in 1% NP40, 0.1% SDS, 5 mM DTT, and 1 mM PMSF for 1 h on ice. Lysates were centrifuged at 20 000g for 5 min to remove nuclei and precipitates. Supernatant protein concentrations were measured using the Bio-Rad protein assay, with BSA in lysis buffer as a standard. Samples containing 80 mg of total cellular protein were subjected to 10-12.5% (depending to the experiments) SDS-PAGE and transferred to a nitrocellulose membrane (Amersham Biotech, France). Equal amounts of total protein lysate were used for each blot. Membranes were blocked for 1 h at room temperature in TBST-0.1% Tween 20/5% nonfat milk. Membranes were then incubated overnight with antibodies directed against b-actin (1:10 000), Bax (1:500), p53 (1:500), p21 (1:500), TRAIL (1:200), PARP (1:500), or caspase-3 (1:200). For signal detection, the secondary mouse or rabbit antibody was used at a dilution of 1:10 000. The blots were washed and developed, using enhanced chemiluminescence (Amersham Biotech, France) according to the manufacturer's protocol, and exposed to radiographic films (Eastman Kodak).
Cell growth kinetics RLE cells were maintained as an adherent monolayer in 25-cm 2 tissue culture flasks in DMEM and 10% FCS. For vector sensitivity experiments, cells were first trypsinized and seeded in 96-well plates (1 Â 10 4 cells per dish) and then allowed to adhere for 24 h. Cells were then incubated with vectors for 1 h; untreated cells received identical manipulation without vector. In mock experiments, cells were treated identically with the AdeGFP vector. Cells were then washed once with PBS and fresh medium was added. Cell growth was measured daily using the 3-(4,5-dimethythiazl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium inner salt (MTT) test. 32 
Analysis of apoptosis
Induction of apoptosis was assessed first by the examination of morphological changes using light microscopy. Apoptosis was evaluated quantitatively by measuring phosphatidylserine externalization, an early apoptotic alteration. 32 This was performed by fluorescence staining using the annexin V-FLUO staining kit (Roche, France) as per the manufacturer's recommendations. The proportion of annexin V-stained cells was determined. FITCpositive cells were scored using a fluorescent microscope (Olympus IX70). Images were recorded with a digital SPOT camera.
Animals
All the rabbits used in this study were cared for and treated in accordance with the ARVO statement for the use of animals in ophthalmic and vision research. Female New Zealand albino rabbits 2.5 to 3 kg in weight and 10-12 weeks of age were used. Only one eye was treated in each animal.
Surgical procedure: phacoemulsification
Rabbits were prepared for phacoemulsification surgery by pretreatment with 0.1% diclofenac sodium ophthalmic solution (Voltaren) and dexamethasone (Chibrocadron). These two sets of drops were applied on the day of the procedure during the hours leading up to surgery. These anti-inflammatory drugs were administrated alternately with mydriatic agents. In all, 1% Atropine Sulfate (Atropine), 2.5% Phenylephrine hydrocloride (Neosynephrine), and 1% Tropicamide (Mydriaticum) ophthalmic drops were started 1 h pre-anesthesia and repeated three times. The rabbits were sedated with 2 mg/kg Nidazolam (Hypnovel ROCHE, Neuilly sur Seine, France), administered intramuscularly and were anesthetized with 60 mg/kg Ketamine administered intramuscularly (Ketalar-Parke-Davis). Rabbits were then placed under an operating microscope. The eye was cleaned with 0.4% iodine solution (Betadine). Sterile Prevention of PCO by gene therapy F Malecaze et al surgical procedures were used. The ocular globe was exposed by retracting the eyelids with a blepharostat. A small corneal incision was made at the limbus with a 3.2 mm blade. High viscosity sodium Hyaluronate (Healon GV) was then injected intracamerally. Then, a 3 mm round capsulorhexis leaving the anterior capsule relatively intact was performed as described by Gwon et al. 26, 27 After hydrodissection of the lens, phacoemulsification was performed using a universal phacoemulsifier (Alcon) and a balanced salt solution (BSS, Alcon) containing 100 UI/ml heparin. Capsular washing was performed with an irrigation aspiration hand piece and at the end of the surgery, no intraocular lens was implanted. Then, the corneal incision was sutured with 10.0 nylon. Upon completion of surgery, a subconjunctival injection of dexamethazone (4 mg/ml) was administrated in a bolus of 0.5 ml into Tenon's capsule. Chlorampenicol 1% ophthalmic ointment was applied to the conjunctiva under both upper and lower lids, and the animal was allowed to recover overnight. At 6 h post-op, anti-inflammatory drops (Voltarene and Chibrocadron) were resumed on a schedule of four times daily for 1 week, declining to three times daily up to 2 weeks post surgery. Twice a day, Neosynephrine and Mydriaticum were also administered in order to mobilize the iris during the first week post surgery.
In vivo transduction with the adenoviral vectors
To optimize contact of the vector with the residual lens epithelial cells, we 'blocked' the small round capsulorhexis by depositing a 'bubble' of Healon GV at the end of the phacoemulsification procedure. Then, once the corneal incision was sutured, we injected the adenoviral vector suspension (100 ml corresponding to 10 8 PFU (particles forming units) of vector, whatever the vector used) inside the closed capsular bag through the Healonobliterated capsulorhexis with a 30 G needle. Diluting the vector suspension with 10% Trypan blue allowed us to ensure that the capsular bag was properly filled and that the vector remained in the bag after surgery. A total of nine rabbits per group received the intracapsular bag injection.
Evaluation of secondary cataract
Postsurgical examinations were made in a double-blind fashion by two examiners. Examinations were performed 2 days after surgery and each week during the 2 months following surgery. Secondary cataract was evaluated after pupil dilatation using a slit lamp biomicroscope, and an operating microscope. The evaluation of secondary cataract was quantified considering the surface of the regenerated opacified area according to Gwon et al. 26 We used a scoring system ranging from 0 to IV, as described previously 9 and shown in Figure 4a .
Evaluation of cell death on corneal endothelium
Following the injections of the different Ad vectors suspensions, the corneas of the animals were excised and stained with 0.4% Trypan blue for 1 min to measure nonspecific cell death.
Evaluation of inflammation
The degree of postoperative inflammation was assessed according to Hogan et al. and Malecaze et al. [33] [34] [35] Briefly, inflammation was clinically evaluated considering the aqueous cellular reaction and flare.
Statistical analyses
Statistical analyses of the in vivo studies were performed using a Mann and Whitney test.
Abbreviations
HSV-tk, herpes simplex virus 1 thymidine kinase; GCV, ganciclovir; FCS, fetal calf serum; CMV, cytomegalovirus; GFP, green fluorescent protein; luc, luciferase; MOI, multiplicity of infection; TUNEL, terminal deoxynucleotidyl transferase-mediated uridine 5 0 -triphosphate nickend labeling.
